Jump Financial LLC Makes New $653,000 Investment in NewAmsterdam Pharma (NASDAQ:NAMS)

Jump Financial LLC purchased a new stake in NewAmsterdam Pharma (NASDAQ:NAMS - Free Report) during the fourth quarter, according to its most recent 13F filing with the SEC. The firm purchased 25,401 shares of the company's stock, valued at approximately $653,000.

A number of other institutional investors have also modified their holdings of NAMS. Jennison Associates LLC boosted its stake in NewAmsterdam Pharma by 291.9% in the 4th quarter. Jennison Associates LLC now owns 3,998,541 shares of the company's stock worth $102,763,000 after purchasing an additional 2,978,263 shares in the last quarter. Wellington Management Group LLP boosted its stake in NewAmsterdam Pharma by 2,410.4% in the 4th quarter. Wellington Management Group LLP now owns 2,315,123 shares of the company's stock worth $59,499,000 after purchasing an additional 2,222,900 shares in the last quarter. Alliancebernstein L.P. acquired a new stake in NewAmsterdam Pharma in the 4th quarter worth approximately $47,752,000. TimesSquare Capital Management LLC boosted its stake in NewAmsterdam Pharma by 250.9% in the 4th quarter. TimesSquare Capital Management LLC now owns 895,574 shares of the company's stock worth $23,016,000 after purchasing an additional 640,329 shares in the last quarter. Finally, American Century Companies Inc. acquired a new stake in NewAmsterdam Pharma in the 4th quarter worth approximately $8,907,000. 89.89% of the stock is currently owned by institutional investors.

Analyst Ratings Changes

A number of analysts recently commented on NAMS shares. HC Wainwright reiterated a "buy" rating and issued a $48.00 target price on shares of NewAmsterdam Pharma in a research note on Tuesday, January 14th. UBS Group set a $41.00 price objective on shares of NewAmsterdam Pharma in a research note on Monday, March 3rd. Scotiabank lifted their price objective on shares of NewAmsterdam Pharma from $47.00 to $52.00 and gave the company a "sector outperform" rating in a research note on Thursday, February 27th. Needham & Company LLC restated a "buy" rating and set a $42.00 price objective on shares of NewAmsterdam Pharma in a research note on Tuesday, April 8th. Finally, Royal Bank of Canada restated an "outperform" rating and set a $40.00 price objective on shares of NewAmsterdam Pharma in a research note on Friday, January 24th. Six investment analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the stock currently has an average rating of "Buy" and an average target price of $43.33.

Insider Transactions at NewAmsterdam Pharma

In other news, Director James N. Topper bought 1,135 shares of the stock in a transaction dated Wednesday, March 26th. The shares were acquired at an average cost of $22.49 per share, with a total value of $25,526.15. Following the purchase, the director now directly owns 3,013,569 shares in the company, valued at $67,775,166.81. The trade was a 0.04 % increase in their position. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. Also, CAO Louise Frederika Kooij sold 150,000 shares of the stock in a transaction dated Tuesday, March 4th. The stock was sold at an average price of $20.37, for a total transaction of $3,055,500.00. Following the sale, the chief accounting officer now directly owns 15,000 shares in the company, valued at approximately $305,550. The trade was a 90.91 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Corporate insiders own 19.50% of the company's stock.

NewAmsterdam Pharma Price Performance

NAMS stock traded up $0.31 during midday trading on Monday, hitting $17.83. 357,200 shares of the stock traded hands, compared to its average volume of 593,679. NewAmsterdam Pharma has a 1-year low of $14.06 and a 1-year high of $27.29. The stock's fifty day simple moving average is $19.58 and its 200-day simple moving average is $21.24. The firm has a market cap of $1.96 billion, a P/E ratio of -6.86 and a beta of -0.01.

NewAmsterdam Pharma (NASDAQ:NAMS - Get Free Report) last posted its earnings results on Wednesday, February 26th. The company reported ($0.95) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.48) by ($0.47). The firm had revenue of $12.77 million for the quarter, compared to analyst estimates of $3.30 million. On average, research analysts predict that NewAmsterdam Pharma will post -1.75 earnings per share for the current year.

About NewAmsterdam Pharma

NewAmsterdam Pharma Company N.V., a late-stage biopharmaceutical company, develops therapies to enhance patient care in populations with metabolic disease. It is developing obicetrapib, an oral low-dose cholesteryl ester transfer protein (CETP) inhibitor, that is in various clinical trials as a monotherapy and a combination therapy with ezetimibe for lowering LDL-C for cardiovascular diseases.